Trastuzumab was once considered potentially effective in HER2-low early breast cancer (16, 17), but the NSABP B-47 study indicated that adding trastuzumab to standard adjuvant therapy did not confer survival benefits to HER2-low patients (10). This evidence concerns the gene ERBB2 and breast carcinoma.